Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode

NCT03870776 is registered in ClinicalTrials.gov with Mapreg as lead sponsor.

NCT NCT03870776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03870776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode
Lead sponsor
Mapreg
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2019
Completion date
November 7, 2024
Enrollment
126 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

depression